State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China; Fudan University Shanghai Cancer Center and Institutes of Biomedical Sciences, Shanghai Medical College, Fudan University, Shanghai, China.
Gastroenterology. 2015 Nov;149(6):1587-1598.e11. doi: 10.1053/j.gastro.2015.07.050. Epub 2015 Aug 3.
BACKGROUND & AIMS: Cancer cells alter glucose metabolism to support their uncontrolled proliferation. Changes in microRNAs (miRNAs) have been associated with colorectal cancer (CRC) development and progression, but it is not clear whether they regulate metabolism in CRC cells. We aimed to identify miRNAs that alter glucose metabolism in CRC cells and to determine their effects on tumor development.
CRC tissues and matched nontumor tissues were collected from 78 patients for messenger RNA (mRNA) analysis and from 112 patients for immunohistochemical analysis at the Fudan University Shanghai Cancer Center from 2005 through 2007. We integrated data on 100 miRNAs previously identified as potential regulators of glucose metabolism in a high-throughput screen with data on 66 miRNAs that often are deregulated in CRC cells. miRNAs with the potential to regulate glucose metabolism in CRC cells were blocked with mimics, and effects on lactate production were measured in CRC cell lines. miRNAs and their targets were overexpressed from lentivirals in CRC cell lines (LoVo and HCT-116) or knocked down with small interfering RNAs. The cells were analyzed in proliferation and colony formation assays and for growth as xenograft tumors in mice.
We identified 3 miRNAs that significantly inhibited lactate production in 3 CRC cell lines; miR124-3p (miR124) had the strongest effect. By using complementary DNA microarray analyses, we identified 67 mRNAs that were reduced in CRC cell lines that overexpressed miR124; the mRNAs encoding phosphoribosyl pyrophosphate synthetase 1 (PRPS1) and ribose-5-phosphate isomerase-A (RPIA) were found to be direct targets of miR124. Knockdown of PRPS1 and RPIA, as well as overexpression of miR124, each reduced glucose consumption and adenosine triphosphate in level CRC cells. Conversely, overexpression of PRPS1 or RPIA restored glycometabolism to these cells. RPIA and PRPS1 contribute to nucleotide metabolism and supply precursors for DNA and RNA biosynthesis. CRC cells that overexpressed miR124 or with knockdown of RPIA or PRPS1 had reduced DNA synthesis and proliferation, whereas cells incubated with an inhibitor of miR124 had significantly increased DNA synthesis and proliferation and formed more colonies. LoVo cells that overexpressed miR124 formed smaller xenograft tumors that controlled cells in mice, and had lower levels of PRPS1 and RPIA mRNA and protein. Compared with normal colorectal tissues, levels of miR124 were reduced significantly in CRC tissues from patients, whereas levels of PRPS1 and RPIA increased, which was associated with reduced patient survival times.
miR124 inhibits DNA synthesis and proliferation by reducing levels of pentose phosphate pathway enzymes in CRC cells. Expression of miR124 and its targets correlate with survival times and might be used in prognosis.
癌细胞改变葡萄糖代谢以支持其不受控制的增殖。微小 RNA(miRNA)的变化与结直肠癌(CRC)的发展和进展有关,但尚不清楚它们是否调节 CRC 细胞中的代谢。我们旨在确定改变 CRC 细胞中葡萄糖代谢的 miRNA,并确定它们对肿瘤发展的影响。
2005 年至 2007 年,复旦大学上海癌症中心从 78 名患者的信使 RNA(mRNA)分析和 112 名患者的免疫组织化学分析中收集 CRC 组织和匹配的非肿瘤组织。我们整合了先前在高通量筛选中鉴定为潜在葡萄糖代谢调节剂的 100 个 miRNA 的数据,以及经常在 CRC 细胞中失调的 66 个 miRNA 的数据。用模拟物阻断有潜力调节 CRC 细胞中葡萄糖代谢的 miRNA,并在 CRC 细胞系中测量乳酸生成的影响。通过慢病毒在 CRC 细胞系(LoVo 和 HCT-116)中过表达 miRNA 及其靶标,或用小干扰 RNA 敲低。在增殖和集落形成测定以及在小鼠中作为异种移植肿瘤生长方面分析细胞。
我们确定了 3 种 miRNA,它们在 3 种 CRC 细胞系中显著抑制乳酸生成;miR124-3p(miR124)的作用最强。通过使用 cDNA 微阵列分析,我们鉴定了在过表达 miR124 的 CRC 细胞系中减少的 67 个 mRNA;编码磷酸核糖焦磷酸合酶 1(PRPS1)和核糖-5-磷酸异构酶-A(RPIA)的 mRNAs 被发现是 miR124 的直接靶标。PRPS1 和 RPIA 的敲低以及 miR124 的过表达均降低了 CRC 细胞中葡萄糖的消耗和三磷酸腺苷水平。相反,PRPS1 或 RPIA 的过表达恢复了这些细胞的糖代谢。RPIA 和 PRPS1 参与核苷酸代谢,并为 DNA 和 RNA 合成提供前体。过表达 miR124 或敲低 RPIA 或 PRPS1 的 CRC 细胞的 DNA 合成和增殖减少,而用 miR124 抑制剂孵育的细胞的 DNA 合成和增殖显著增加,并形成更多集落。过表达 miR124 的 LoVo 细胞形成较小的异种移植肿瘤,控制小鼠中的细胞,PRPS1 和 RPIA mRNA 和蛋白水平较低。与正常结直肠组织相比,患者 CRC 组织中 miR124 的水平显著降低,而 PRPS1 和 RPIA 的水平升高,这与患者生存时间缩短有关。
miR124 通过降低 CRC 细胞中戊糖磷酸途径酶的水平来抑制 DNA 合成和增殖。miR124 及其靶标的表达与生存时间相关,可用于预后。